Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.

Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin Lung Cancer. 2020 05; 21(3):232-237.

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Cell-Free Nucleic Acids
Disease Progression
ErbB Receptors
Erlotinib Hydrochloride
Female
Follow-Up Studies
Humans
Incidence
Lung Neoplasms
Male
Middle Aged
Mutation
Prognosis
Retrospective Studies
Survival Rate

authors with profiles

Marina Chiara Garassino